Should 1 year of atezolizumab be the standard of care for stage II-IIIA resected PDL1+ NSCLC?

The gold standard endpoint for trials for patients with curable NSCLC has been overall survival. If a therapy delays disease recurrence, but does not impact survival, one could argue that it should not be used in the adjuvant setting and used at the time of recurrence and similar benefits and overal...

Yes – currently adjuvant atezolizumab for 1 year following adjuvant chemotherapy should be discussed and offered as SOC for patients with PD-L1+ stage II-IIIA NSCLC. While OS remains the gold standard by which we evaluate the impact of any form of therapy in the setting of disease treated with curat...